Vitamin K antagonists

Quick revision

A vitamin K antagonist does not touch clotting factors that already exist; it stops the liver making new working ones, and almost every practical feature of the class — the slow start, the blood test, the food and drug interactions, the antidote — follows from that single fact.

• Warfarin competitively inhibits vitamin K epoxide reductase complex subunit 1, the enzyme that turns used vitamin K back into the active form the liver needs. (1)
• Vitamin K is the cofactor for building clotting factors II, VII, IX and X, and also the natural brakes on clotting, protein C and protein S; blocking the recycling enzyme reduces all six. (1) (5)
• Clotting factors already circulating are unaffected, so the drug works only as those existing factors are used up — the onset of action is given as one to three days and the peak effect as several days after starting. (1)
• Protein C levels fall before the clotting factors do, creating a short prothrombotic window at the start of treatment, which is why another anticoagulant is given alongside when a clot is already present. (7) (2)
• The international normalized ratio, or INR, is the prothrombin time expressed as a standardised ratio, and it is the preferred parameter for monitoring anyone taking a vitamin K antagonist. (4)
• Warfarin is a racemic mixture, and the S-enantiomer is roughly three to five times more potent than the R-enantiomer, so interactions that hit the enzyme clearing S-warfarin matter most. (1) (2)
• S-warfarin is cleared mainly by CYP2C9, and reduced-function CYP2C9 alleles cut its clearance substantially, which is one reason the dose that suits one patient can be badly wrong for another. (1)
• Vitamin K in food works directly against the drug, so patients are advised to keep their intake of vitamin K-rich foods steady rather than to avoid those foods altogether. (1)
• Antimicrobials are among the most frequent interacting drug classes, and metronidazole, trimethoprim-sulfamethoxazole and ciprofloxacin interfere directly by inhibiting warfarin metabolism. (2)
• Enzyme inducers pull in the opposite direction: rifampin, and phenytoin taken long term, increase warfarin metabolism and lower the INR. (2)
• Warfarin-induced skin necrosis usually appears within the first week and reflects an acquired protein C deficiency, with greatest risk in people who already lack protein C or protein S. (1) (2)
• Purple toe syndrome is a separate and much later problem, caused by cholesterol microembolisation and typically appearing several weeks after treatment begins. (1)
• Warfarin crosses the placenta and is contraindicated in pregnancy apart from selected patients with mechanical heart valves at high thromboembolic risk. (1) (2)
• Unlike the antiplatelet drugs, this class has a specific antidote: vitamin K, given as phytonadione, with four-factor prothrombin complex concentrate added when correction has to be immediate. (1) (6) (7)

Overview

Vitamin K antagonists are oral anticoagulants that work indirectly. They do not attack a clotting factor or dissolve a clot; they interfere with the liver's ability to finish making certain clotting proteins. Warfarin is the agent that dominates the class and the one on which the sources here are based. It is used to prevent and treat venous thrombosis and pulmonary embolism, to prevent clots that form because of atrial fibrillation or a replaced heart valve, to lower the risk of death and further events after a heart attack, and to prevent a second stroke or transient ischaemic attack. (1) (2)

The mechanism runs through a small recycling loop. Vitamin K acts as a cofactor for an enzyme that adds carboxyl groups to specific glutamate residues on newly made clotting proteins, and that modification is what lets those proteins bind calcium and take part in the clotting cascade. Every time the reaction runs, vitamin K is oxidised to an inactive epoxide, and an enzyme called vitamin K epoxide reductase converts it back. Warfarin competitively inhibits that reductase, so the pool of usable vitamin K falls and the liver releases clotting proteins that are structurally present but functionally useless. (5) (1)

Everything awkward about the class follows from this. Because the drug only affects newly made protein, its effect appears slowly and disappears slowly, and it cannot be relied on in the first days of an acute clot without cover from a faster anticoagulant. Because the supply of the cofactor comes partly from food, what a patient eats changes the answer. Because warfarin is a narrow-margin drug cleared by cytochrome P450 enzymes, a large number of medicines and herbal products shift it out of range in one direction or the other. And because none of that is predictable in an individual, the effect has to be measured directly, using the international normalized ratio. (2) (1) (4)

The trade-off is bleeding, which can occur at almost any site and includes bleeding into the brain and the gastrointestinal tract. Set against that, this class has something the newer oral anticoagulants and the antiplatelet drugs largely lack: a cheap, specific, mechanistically obvious antidote in vitamin K, backed up by factor replacement when correction has to be immediate. Guidance now favours direct oral anticoagulants over vitamin K antagonists for most patients with atrial fibrillation or venous thromboembolism, but vitamin K antagonists remain the preferred option in defined situations, including moderate-to-severe mitral stenosis and mechanical heart valves. (1) (7)

Classification and drug examples

The therapeutic side of this class is effectively one drug in the sources consulted here. It is still worth separating from the long-acting compounds that share the same mechanism but exist as poisons rather than medicines, because they behave very differently once inside a patient.

Mechanism of action

Warfarin blocks the enzyme that regenerates usable vitamin K. Without that cofactor, the liver cannot carry out the carboxylation step that lets clotting factors II, VII, IX and X and the anticoagulant proteins C and S bind calcium, so the proteins are secreted in a form that cannot participate in the cascade.

Molecular target

Vitamin K epoxide reductase complex subunit 1 (VKORC1) in the hepatocyte, and through it the vitamin K-dependent carboxylation of factors II, VII, IX and X and proteins C and S

1. Clotting factors need a chemical finishing step

   Several clotting proteins are made in the liver in an unfinished form. An enzyme adds a second carboxyl group to particular glutamate residues, converting them into gamma-carboxyglutamate residues. Only then can the protein grip calcium ions and dock onto the cell surfaces where clotting happens. (5)

2. Vitamin K is the cofactor for that step, and it is recycled

   The carboxylating enzyme uses reduced vitamin K, and in doing so oxidises it to vitamin K epoxide. Vitamin K epoxide reductase converts the epoxide back to the usable form. This loop, the vitamin K cycle, is why a small dietary supply is normally enough. (5)

3. Warfarin blocks the recycling enzyme

   Warfarin competitively inhibits vitamin K epoxide reductase complex subunit 1, so vitamin K accumulates in its spent form and the supply of the reduced cofactor runs down. The carboxylating enzyme then has nothing to work with. (1) (5)

4. Six proteins come out non-functional

   Factors II, VII, IX and X are released without enough gamma-carboxyglutamate ends, so they cannot bind properly at the site of vessel injury and no stable clot forms. The natural anticoagulants protein C and protein S depend on the same modification and fall too. (5) (1)

5. The effect waits for existing factors to disappear

   Factors already in the circulation are untouched, so anticoagulation only develops as they are consumed and are not replaced. The onset of action is described as one to three days, with peak effect several days after starting, even though the tablet itself is absorbed within hours. (1)

6. Protein C falls first, creating an early prothrombotic window

   Protein C has a short survival in the circulation, so it disappears before the procoagulant factors have fully declined. That imbalance underlies both the need for cover with another anticoagulant when treating an established clot and the early appearance of warfarin-induced skin necrosis. (7) (2)

7. The INR reads the result rather than the drug level

   The prothrombin time measures the extrinsic and common pathways, where the vitamin K-dependent factors sit, and the INR standardises that measurement for the reagent a laboratory uses. Monitoring therefore reports the biological effect achieved, not the concentration of warfarin present. (4) (1)

8. Vitamin K reverses the block by refilling the substrate pool

   Giving vitamin K restores the cofactor supply so carboxylation resumes, which is why the antidote is the vitamin itself rather than a drug that displaces warfarin. Correction still takes hours, because new functional factors must be synthesised, which is why concentrated factors are added when bleeding cannot wait. (5) (6)

Major clinical uses

Pharmacokinetics

• In a rise in INR after an acute overdose, the delay before the reading moves reflects the survival of factor VII, and the source notes the prothrombin time may not begin to rise for several hours after ingestion in someone not already taking the drug. (3)
• Reduced kidney function does not call for a different dosing rule, but it does allow the drug to accumulate and raises bleeding risk, so closer monitoring rather than a formulaic change is what the source describes. (1)
• Liver disease and alcohol move the pharmacokinetics unpredictably: an acute drink slows warfarin metabolism while sustained heavy drinking induces the enzymes and speeds it, so the direction of the shift depends on the pattern of intake. (3) (2)
• This page gives no dose regimens by design. Doses depend on indication, target range, comorbidity, genotype, diet and interacting medicines, and belong in a prescribing reference used by the treating clinician.

Adverse effects

Common

• Easy bruising and minor bleeding: Bruising, nosebleeds and bleeding from small cuts are the everyday expression of reduced clotting factor activity, and patients are counselled on how to manage them and when to report them. (1)
• Gastrointestinal upset: Nausea, vomiting, abdominal pain, bloating, wind and an altered sense of taste are listed among the non-bleeding effects. (1)
• Unstable INR readings: Not an adverse effect of the tablet in the usual sense, but the commonest practical problem: diet, alcohol, thyroid state, illness and newly started medicines all move the result, and each move carries either bleeding or clotting risk. (2) (4)

Serious adverse effects

• Major haemorrhage: Serious bleeding can happen at almost any site, and the named examples include bleeding into the brain, the gastrointestinal tract, the eye and a joint, as well as vomiting blood. Risk rises with the intensity of anticoagulation and with individual susceptibility. Assessed urgently. Management as described begins with stopping anticoagulant and antiplatelet drugs where possible, stabilising the circulation, controlling bleeding locally and transfusing, with specific reversal reserved for life-threatening or critical-site bleeding. (1) (7)
• Warfarin-induced skin necrosis: Tissue death in the skin and the fat beneath it, beginning within days of starting treatment. It follows an acquired protein C deficiency and the risk is higher in people who already have a protein C or protein S deficiency. Managed as described by stopping warfarin, giving fresh frozen plasma and vitamin K, and continuing anticoagulation with unfractionated or low-molecular-weight heparin instead. (1) (2)
• Purple toe syndrome and systemic cholesterol microembolisation: Purple lesions on the toes and the sides of the feet, caused by cholesterol microemboli released after warfarin is started. The source places it typically several weeks into treatment rather than in the first days. Recognised as a reason to reconsider the choice of anticoagulant; alternative therapy merits consideration where severe effects occur on warfarin. (1) (2)
• Calciphylaxis: Calcific uraemic arteriolopathy, involving vascular calcification and skin necrosis, has been reported in patients on warfarin with and without end-stage kidney disease. A rare but recognised reason to review whether a vitamin K antagonist remains the right agent for that patient. (1) (2)
• Fetal harm: Warfarin crosses the placenta and produces fetal levels similar to the mother's. It is associated with bleeding in the fetus, miscarriage, stillbirth, preterm birth and neonatal death, and with a pattern of malformations described as fetal warfarin syndrome. Pregnancy status is established before treatment, and the drug is avoided in pregnancy other than in selected patients with mechanical heart valves at high thromboembolic risk. (1) (2)
• Anticoagulant-related nephropathy: Bleeding into the glomerulus with red cell casts obstructing the tubules, presenting with blood in the urine, raised blood pressure, fluid overload and reduced urine output. Considered when kidney function deteriorates in an anticoagulated patient rather than being attributed automatically to another cause. (7)

Drug-specific effects

• Warfarin: The class signature is the combination of skin necrosis in the first week, purple toe syndrome weeks later, and accelerated vascular calcification — none of which is shared with the direct oral anticoagulants. (1) (7)
• Warfarin: Bleeding risk rises with age, and the source attributes this to falls, interacting medicines, cognitive state and unsafe living conditions rather than to age alone. (1)
• Superwarfarin rodenticides: Prolonged coagulopathy is the defining problem; because these compounds outlast a short course of antidote, the anticoagulant effect can persist for far longer than after a therapeutic warfarin overshoot. (3)

Contraindications, precautions and interactions

Contraindications

• Active ulceration or bleeding in the gastrointestinal tract, or bleeding from the respiratory or genitourinary tract. (1)
• Bleeding associated with pericarditis, pericardial effusion or bacterial endocarditis. (1)
• Epidural or spinal puncture, and major regional or lumbar block anaesthesia, along with other procedures carrying a significant bleeding risk. (1)
• Recent or planned surgery of the eye or central nervous system, or traumatic surgery leaving large raw surfaces. (1)
• Pregnancy, except in patients with a mechanical heart valve at high risk of thromboembolism; also threatened miscarriage, pre-eclampsia and eclampsia. (1) (2)
• Hypersensitivity to warfarin or to any component of the formulation. (1)
• Malignant hypertension, because of the risk of bleeding into the brain at extremely high blood pressure. (2)

Precautions

• Situations where reliable monitoring or reliable tablet-taking cannot be arranged; unsupervised patients at high risk of not following treatment are listed as a contraindication in their own right. (1)
• Older patients, in whom falls, interacting medicines and cognitive difficulties raise bleeding risk and closer monitoring is described. (1)
• Obstructive jaundice, hepatitis and cirrhosis, where sensitivity to oral anticoagulants may be increased even though the manufacturer states no routine adjustment is required. (1)
• Reduced kidney function, which allows accumulation and raises bleeding risk although it does not itself dictate a different dosing rule. (1)
• Known protein C or protein S deficiency, because the fall in protein C at the start of treatment is what precipitates skin necrosis. (1) (2)
• Breastfeeding is described as compatible, since warfarin is not excreted in breast milk, but the manufacturer advises watching the infant for bruising or bleeding. (1)

Drug interactions

• Dietary vitamin K: Foods rich in vitamin K, such as kale, spinach, Brussels sprouts and green tea leaves, oppose the drug's effect. Advice centres on keeping intake consistent rather than eliminating those foods. (1)
• CYP2C9 inhibitors, including metronidazole, trimethoprim-sulfamethoxazole and ciprofloxacin: These slow the clearance of the more potent S-enantiomer and raise the INR; the source classes them as major interactions and advises avoiding the combination where possible. (2)
• Amiodarone: Potentiates warfarin by two routes at once — inhibiting its metabolism, and with prolonged use altering thyroid function, since increased thyroid activity speeds the breakdown of vitamin K-dependent clotting factors and raises the INR further. (2)
• Enzyme inducers such as rifampin and long-term phenytoin: Speed warfarin metabolism and lower the INR, so the risk shifts from bleeding to clotting. Phenytoin can act in both directions, raising the INR when first started by displacing warfarin from protein binding sites. (2)
• Other drugs affecting haemostasis — antiplatelet agents, non-steroidal anti-inflammatory drugs and selective serotonin reuptake inhibitors: Raise bleeding risk even when the INR does not change, which is why an in-range result does not on its own make a combination safe. (2)
• Salicylates: Add bleeding risk through three separate routes: inhibition of platelet aggregation, irritation of the stomach lining, and displacement of warfarin from protein binding sites so that more free drug circulates. (2)
• Alcohol: Acts in opposite directions depending on the pattern of use: a single heavy episode inhibits warfarin metabolism and raises the INR, while sustained heavy drinking induces liver enzymes and lowers it, on top of the gastrointestinal bleeding risk. (2)
• Herbal products, including green tea and American ginseng: Green tea has been associated with a lower INR because of its vitamin K content, and American ginseng lowered the INR in a small randomised study; standardisation of these products is poor, which makes the interactions hard to quantify. (2)
• Drugs affecting absorption, such as bile acid sequestrants and sucralfate: These are the interactions where separating the times of administration can help, unlike metabolic interactions where changing the timing does not avoid the problem. (2)

Comparison tables

High-yield exam pearls

• The named molecular target is vitamin K epoxide reductase complex subunit 1, usually written VKORC1. (1) (5) Questions often accept only the enzyme name rather than the vague answer that warfarin 'blocks vitamin K'. Warfarin does not destroy vitamin K; it blocks the recycling step that regenerates the usable form.
• Six proteins are affected, not four: factors II, VII, IX and X plus proteins C and S. (1) (7) The two anticoagulant proteins are the half that explains warfarin's early prothrombotic window and its most distinctive skin reaction, so leaving them out loses the reasoning behind both.
• Warfarin's slow onset is a property of the clotting system, not of the tablet. (1) The drug is absorbed rapidly and reaches peak plasma concentration within hours, but the anticoagulant effect waits for circulating clotting factors to be used up, which is why the source gives an onset of one to three days.
• An INR of about one is what an untreated person has, and the number is a multiple of normal clotting time. (1) (4) Reading the INR as a multiple makes the whole test intuitive: a patient at two takes about twice as long to clot as an untreated person. That framing is more useful in an exam than memorising target numbers.
• Warfarin has a narrow therapeutic index, which is the underlying reason interactions matter so much. (2) A small shift in exposure moves the patient out of the useful range in one direction or the other, so drugs that would be unremarkable with a wider-margin medicine become clinically significant here.
• Warfarin-induced skin necrosis and purple toe syndrome are separated by their timing and their mechanism. (1) (2) Necrosis is early and caused by falling protein C; purple toe syndrome comes weeks later and is caused by cholesterol microemboli. Exams commonly test that pairing rather than either lesion alone.
• Vitamin K given by mouth works, but not quickly; the intravenous route is what corrects the INR fastest among vitamin K options. (1) (5) The source describes the effect of an intravenous dose beginning within a few hours and the oral route taking about a day, while the subcutaneous route is discouraged because absorption from fat is erratic.
• Warfarin cannot be removed by haemodialysis. (1) It is heavily protein bound, so dialysis is not a route out of an overdose, and this is a common distractor in questions about managing warfarin toxicity in a patient with kidney disease.
• Superwarfarin rodenticides act by the same mechanism but last far longer. (3) They are described as around a hundred times as potent as warfarin, so a poisoning can need vitamin K for a prolonged period rather than the short course that follows a therapeutic overshoot.

Common exam traps

• Trap: Saying that warfarin thins the blood already in the circulation. Actually: It has no effect on clotting factors that are already made and no ability to dissolve a clot that already exists; it only reduces the production of new working factors. (2)
• Trap: Expecting the INR to reflect the full anticoagulant effect as soon as it starts rising. Actually: The INR responds first to the fall in factor VII, which has the shortest survival in the circulation, so an early rise can appear before the other factors have declined and the patient is genuinely anticoagulated. (3) (1)
• Trap: Telling a patient to avoid green vegetables entirely. Actually: The source advises consistent intake rather than avoidance, because the problem is fluctuation in vitamin K intake rather than the vitamin itself; abrupt changes in either direction destabilise the INR. (1)
• Trap: Assuming every interacting drug pushes the INR up. Actually: Interactions run both ways. Enzyme inhibitors and drugs displacing warfarin from protein raise the INR, while enzyme inducers such as rifampin and long-term phenytoin lower it and increase the risk of clotting instead. (2)
• Trap: Treating an unchanged INR as proof that a combination is safe. Actually: Any drug that impairs clotting — another anticoagulant, an antiplatelet agent, a non-steroidal anti-inflammatory drug or a selective serotonin reuptake inhibitor — raises bleeding risk even when the INR does not move. (2)
• Trap: Blaming a supratherapeutic INR on the tablets alone. Actually: Diet, alcohol, thyroid status, herbal products, liver disease and newly started medicines all shift the INR, so the source directs that recent changes in all of those be sought rather than only the anticoagulant reviewed. (2) (3)
• Trap: Assuming a normalised INR after treated warfarin toxicity means the episode is over. Actually: Rebound has been reported: patients whose INR normalised after vitamin K have returned days later with bleeding and a supratherapeutic INR again, which is why follow-up rather than discharge alone is described. (3)

Self-test questions

Answers are hidden until you open them. These questions are written from this page's cited content and are for study only — they are not clinical guidance.

1. Which enzyme does warfarin competitively inhibit?

   • Gamma-glutamyl carboxylase
   • Vitamin K epoxide reductase complex subunit 1
   • Antithrombin III
   • Cyclooxygenase-1
   Show answer

   Answer: Vitamin K epoxide reductase complex subunit 1

   Warfarin competitively inhibits vitamin K epoxide reductase complex subunit 1, the enzyme that regenerates usable vitamin K. Depleting the active vitamin K supply starves the carboxylation step that clotting factor production depends on. (1) (5)

2. Which set of proteins is reduced by a vitamin K antagonist?

   • Factors II, VII, IX and X only
   • Factors II, VII, IX and X, plus proteins C and S
   • Factors V and VIII, plus von Willebrand factor
   • Fibrinogen and plasminogen
   Show answer

   Answer: Factors II, VII, IX and X, plus proteins C and S

   Vitamin K is the cofactor for the clotting factors II, VII, IX and X and also for the natural anticoagulants protein C and protein S. Reducing all six is what produces both the therapeutic effect and the transient prothrombotic window at the start. (1) (7)

3. Why is a second anticoagulant usually given alongside warfarin when treating an acute clot?

   • Warfarin is inactivated by the clot itself
   • Protein C falls faster than the clotting factors, so there is a brief prothrombotic period at the start
   • Warfarin cannot be absorbed while a thrombus is present
   • The second drug is needed to keep the INR from rising too fast
   Show answer

   Answer: Protein C falls faster than the clotting factors, so there is a brief prothrombotic period at the start

   Protein C is a natural anticoagulant with a short survival in the circulation, so its level drops before the procoagulant factors do. That early imbalance is why cover with another anticoagulant is described during the first days of treatment. (7) (2)

4. Which enzyme clears the more potent enantiomer of warfarin?

   • CYP2D6
   • CYP2C19
   • CYP2C9
   • CYP1A2
   Show answer

   Answer: CYP2C9

   Warfarin is a racemic mixture whose S-enantiomer is several times more potent than the R-enantiomer, and S-warfarin is metabolised chiefly by CYP2C9. Interactions and genetic variants at CYP2C9 therefore have the largest effect on the achieved level of anticoagulation. (1) (2)

5. A patient stabilised on warfarin starts rifampin. What is the expected effect on the INR?

   • It falls, because rifampin induces the enzymes that metabolise warfarin
   • It rises, because rifampin inhibits warfarin metabolism
   • It is unchanged, because rifampin does not interact with warfarin
   • It becomes unmeasurable
   Show answer

   Answer: It falls, because rifampin induces the enzymes that metabolise warfarin

   Rifampin is a cytochrome P450 inducer, so it speeds warfarin metabolism and the INR falls. The clinical risk here is thrombosis from under-anticoagulation rather than bleeding. (2)

6. A patient develops painful skin lesions progressing to necrosis during the first week of warfarin. What is the underlying mechanism?

   • An immune reaction to the tablet coating
   • Cholesterol microembolisation from ulcerated plaque
   • Acquired protein C deficiency causing microvascular thrombosis
   • Direct toxicity of warfarin to skin keratinocytes
   Show answer

   Answer: Acquired protein C deficiency causing microvascular thrombosis

   Warfarin-induced skin necrosis follows the fall in protein C, a natural anticoagulant, which leaves small vessels in the skin prone to thrombosis. Risk is highest in people with an existing protein C or protein S deficiency. (1) (2)

7. Which statement about monitoring a vitamin K antagonist is correct?

   • The activated partial thromboplastin time is the standard test
   • Anti-factor Xa activity is the preferred routine measure
   • The international normalized ratio, derived from the prothrombin time, is the preferred parameter
   • No routine laboratory monitoring is needed
   Show answer

   Answer: The international normalized ratio, derived from the prothrombin time, is the preferred parameter

   The INR is the preferred parameter for monitoring patients taking vitamin K antagonists. It expresses the prothrombin time as a ratio standardised for the potency of the laboratory's thromboplastin reagent, so results are comparable between laboratories. (4)

8. Which combination is described for rapid, sustained reversal of warfarin-associated major bleeding?

   • Protamine sulfate alone
   • Four-factor prothrombin complex concentrate together with intravenous vitamin K
   • Idarucizumab
   • Tranexamic acid alone
   Show answer

   Answer: Four-factor prothrombin complex concentrate together with intravenous vitamin K

   Four-factor prothrombin complex concentrate corrects the factor deficit within minutes, and intravenous vitamin K is given with it so the correction is sustained once the concentrate is cleared. Fresh frozen plasma is described as a less effective alternative when the concentrate is unavailable. (7) (6)

9. Why is haemodialysis not a route of removal in warfarin overdose?

   • Warfarin is destroyed by the dialysis membrane
   • Warfarin is almost entirely protein bound and cannot be removed by dialysis
   • Dialysis raises the INR further
   • Warfarin is eliminated unchanged in bile
   Show answer

   Answer: Warfarin is almost entirely protein bound and cannot be removed by dialysis

   Warfarin is about ninety-nine per cent protein bound and has a small volume of distribution, and the source states directly that it cannot be removed through haemodialysis. Management therefore relies on stopping the drug and giving vitamin K, with factor replacement where bleeding is serious. (1)

Frequently asked questions

References

1. Warfarin (StatPearls) StatPearls Publishing / NCBI Bookshelf, 2024
2. Warfarin Drug Interactions (StatPearls) StatPearls Publishing / NCBI Bookshelf, 2023
3. Warfarin Toxicity (StatPearls) StatPearls Publishing / NCBI Bookshelf, 2023
4. International Normalized Ratio: Assessment, Monitoring, and Clinical Implications (StatPearls) StatPearls Publishing / NCBI Bookshelf, 2025
5. Vitamin K (StatPearls) StatPearls Publishing / NCBI Bookshelf, 2023
6. Prothrombin Complex Concentrate (StatPearls) StatPearls Publishing / NCBI Bookshelf, 2024
7. Anticoagulation Safety (StatPearls) StatPearls Publishing / NCBI Bookshelf, 2026

Related drug classes

• Antiplatelet agents
• Direct oral anticoagulants
• Heparins and related parenteral anticoagulants
• Thrombolytics

Back to the Cardiovascular drugs classification · Pharmacology Study Corner